首页> 外文期刊>Vaccine >Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B
【24h】

Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B

机译:白喉,破伤风,脱细胞百日咳,灭活脊髓灰质炎联合疫苗用于重组乙型肝炎的冻干乙型流感嗜血杆菌疫苗(DTaP-IPV // PRP-T)的免疫原性研究

获取原文
获取原文并翻译 | 示例
           

摘要

This study was designed to assess the immunogenicity of a vaccine combining diphtheria and tetanus toxoids, acellular pertussis vaccine, and inactivated poliovirus vaccine reconstituting Haernophilus inflttenzae type b polysaccharide conjugated to tetanus protein (DTaP-IPV//PRP-T; Pasteur Merieux Connaught, Lyon, France) administered simultaneously in association with hepatitis B vaccine (RECOMBIVAX Merck, Sharp & Dohme, West Point. PA, USA) for the primary immunization of infants. The vaccines were administered at two, three and four months of age. One hundred and sixty-two healthy infants; aged 8-10 weeks, were enrolled in the study. Blood samples were taken before the first dose and 4 weeks after the third dose. The infants were observed for 15 minutes after vaccination for any immediate reaction. Adverse events requiring a medical consultation were recorded by the parents in a diary over the 7 days following vaccination. Four weeks after the third immunization, the percentages of infants fulfilling seroconversion criteria were 98.9% for pertussis toxin, 95.9% for filamentous haemagglutinin, 100.0% for tetanus, 100.0% for diphtheria, 99.3% for poliovirus type 1, 100.0% for both poliovirus types 2 and 3, 98.0% for Haemophilus influe,zae type b, and 100% for hepatitis B surface antigen. No vaccine-related serious adverse event was reported. The simultaneous administration of DTaP-IPV//PRP-T and hepatitis B vaccines at two, three and four months of age yielded clinically satisfactory immune responses to all antigens compared with historical controls and gave a good safety profile.
机译:这项研究旨在评估结合白喉和破伤风类毒素的疫苗,无细胞百日咳疫苗和灭活脊髓灰质炎病毒疫苗的免疫原性,该疫苗重组了与破伤风蛋白结合的嗜血性流感嗜血杆菌b型多糖(DTaP-IPV // PRP-T; Pasteur Merieux Connaught,里昂(法国)与乙型肝炎疫苗(RECOMBIVAX Merck,Sharp&Dohme,West Point。PA,USA)同时施用,用于婴儿的初次免疫。疫苗分别在两个,三个和四个月大时施用。 162名健康婴儿;年龄为8-10周的孩子被纳入研究。在第一剂之前和第三剂之后4周采集血样。接种疫苗后观察婴儿15分钟是否有任何即时反应。接种疫苗后7天内,父母在日记中记录了需要医疗咨询的不良事件。第三次免疫后四周,符合血清转换标准的婴儿百日咳毒素的百分比为98.9%,丝状血凝素为95.9%,破伤风为100.0%,白喉为100.0%,脊髓灰质炎1型为99.3%,两种脊髓灰质炎病毒为100.0%在图2和图3中,流感嗜血杆菌(zae型b)为98.0%,乙肝表面抗原为100%。没有报告疫苗相关的严重不良事件。与历史对照相比,在两个,三个和四个月大时同时施用DTaP-IPV // PRP-T和乙型肝炎疫苗可产生对所有抗原的临床令人满意的免疫反应,并具有良好的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号